We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00867113
Recruitment Status : Completed
First Posted : March 23, 2009
Last Update Posted : August 28, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST.

Condition or disease Intervention/treatment Phase
Gastrointestinal Stromal Tumor (GIST) Drug: imatinib mesylate Phase 2

Detailed Description:
This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The primary endpoint is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST. A total of 85 adult patients, 18 years of age and older will be enrolled.Participants will take 400 mg of imatinib mesylate daily by mouth for a total of 5 years. At the conclusion of the treatment period, patients will be followed for 2 years for survival, status of response and antineoplastic treatments and quality of life.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 91 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Actual Study Start Date : July 22, 2009
Primary Completion Date : December 20, 2016
Study Completion Date : December 20, 2016

Arm Intervention/treatment
Experimental: Imatinib Mesylate
Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Drug: imatinib mesylate
imatinib mesylate 400 mg once per day by mouth for 5 years.

Primary Outcome Measures :
  1. Time to recurrence [ Time Frame: Five years ]

Secondary Outcome Measures :
  1. safety and tolerability of five year adjuvant therapy with imatinib [ Time Frame: Five years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients 18 years of age or older.
  2. Patient must have a histological diagnosis of primary GIST.
  3. The tumor must express KIT (CD117) protein by immunohistochemistry performed by central pathology.
  4. Patient must be at significant risk of tumor recurrence as defined by either:

    • Primary GIST (any site): ≥ 2 cm and a mitotic rate of ≥ 5/50 HPF's
    • Non-gastric primary GIST: ≥ 5cm
  5. Patient must have undergone complete gross resection of a primary GIST within 12 weeks prior to first dose of imatinib study drug. The inclusion of R1 resections will be reviewed on a case by case basis by the Study Management Committee.
  6. Patient must have no evidence of metastatic GIST on either 1) a post-operative CT of the abdomen and pelvis with intravenous and oral contrast or 2) MRI of the abdomen and pelvis with intravenous contrast. CT or MRI must be performed within 8 weeks prior to first dose of imatinib study drug.
  7. Performance status 0 or 1 (ECOG)
  8. Patient must have the following post-operative laboratory values confirmed within 14 days prior to first dose of imatinib study drug:

    • total bilirubin < 1.5 x ULN NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study.
    • ALT and AST < 2.5 x ULN
    • creatinine < 1.5 x ULN
    • ANC > 1.5 x 109/L
    • platelets > 100 x 109/L
  9. If patient is a cancer survivor, ALL of the following criteria apply:

    • Patient has undergone potentially curative therapy for all prior malignancies.
    • No evidence of any prior malignancies for at least 3 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone).
    • Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.
  10. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 7 days following discontinuation of study drug.
  11. Written, voluntary informed consent.

Exclusion Criteria:

  1. Patient has metastatic GIST to the peritoneum, liver, lymph node, or other sites or recurrent GIST.
  2. Prior treatment for GIST with the exception of prior treatment with imatinib adjuvant lasting ≤ 8 weeks following gross surgical resection.
  3. Patient has received any other investigational agents within 28 days of first day of study drug dosing.
  4. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
  5. Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risk or compromise compliance with the protocol (i.e., uncontrolled diabetes, chronic renal disease, chronic liver disease, or active uncontrolled infection).
  6. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
  7. Patient receiving concurrent treatment with warfarin (acceptable alternative: low-molecular weight heparin).
  8. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00867113

  Hide Study Locations
United States, California
University of California San Diego - Moores Cancer Center Moores UCSD Cancer Center (31)
La Jolla, California, United States, 92093-0658
United States, Colorado
University of Colorado University of Colorado
Aurora, Colorado, United States, 80045
United States, District of Columbia
Washington Hospital Center Department of Medical Oncology
Washington, D.C., District of Columbia, United States, 20010
United States, Georgia
University Cancer & Blood Center, LLC
Athens, Georgia, United States, 30607
Longstreet Cancer Center
Gainesville, Georgia, United States, 30501
United States, Idaho
Kootenai Medical Center Kootenai Cancer Cancer
Coeur d'Alene, Idaho, United States, 83814
United States, Illinois
North Shore University Health System
Evanston, Illinois, United States, 60201
United States, Massachusetts
Dana Farber Cancer Institute Dana-Farber
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Institute Karmonos Cancer Instit. (40)
Detroit, Michigan, United States, 48201
United States, Missouri
Washington University School of Medicine Center for Advanced Medicine
Saint Louis, Missouri, United States, 63110
United States, Nevada
Southern Nevada Cancer Research Foundation S. Nevada Cancer Res (2)
Las Vegas, Nevada, United States, 89106
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New York
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (7)
New York, New York, United States, 10021
United States, North Carolina
Duke University Medical Center Duke University Med Ctr (8)
Durham, North Carolina, United States, 27710
United States, Oregon
Oregon Health & Science University OHS University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Penn State University / Milton S. Hershey Medical Center Penn Stat University
Hershey, Pennsylvania, United States, 17033-0850
United States, Rhode Island
Roger Williams Medical Center Medical Center
Providence, Rhode Island, United States, 02908
United States, Tennessee
Kingport Hematology Oncology
Kingsport, Tennessee, United States, 37660
United States, Texas
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (4)
Houston, Texas, United States, 77030
South Texas Oncology and Hematology, PA South Texas Onc/Hem
San Antonio, Texas, United States, 78259
United States, Virginia
Virginia Oncology Associates Viriginia Oncology Assoc.
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00867113     History of Changes
Other Study ID Numbers: CSTI571BUS282
First Posted: March 23, 2009    Key Record Dates
Last Update Posted: August 28, 2017
Last Verified: August 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Protein Kinase Inhibitors
Gastrointestinal Stromal Tumors
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action